Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window In 2024, several research and pharmacological ...

A new study published in the Asian Journal of Psychiatry showed that people of Indian heritage require lower effective ...

(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) Monday said data from Phase 3 KINECT-3 and KINECT-4 studies showed that treatment with Ingrezza brought holistic improvements over time in patients with ...

A 28-year-old Middle Eastern man develops severe motor disturbances, including muscle rigidity, tremors, a parkinsonian gait, and involuntary, jerky limb movements, following the administration of a 3 ...

The FDA's REMS program has been found to have unintentionally created barriers to accessing clozapine, a crucial ...

Lyu X, Li Z, Chen S, et al. Transcranial direct current stimulation improves tardive dyskinesia in long-term hospitalized patients with chronic schizophrenia. Clin Neurophysiol. 2024;166:20-30. doi:10 ...

SAN DIEGO - Neurocrine (NASDAQ:NBIX) Biosciences, Inc. (NASDAQ:NBIX) revealed study results indicating that nearly 60% of participants achieved remission of tardive dyskinesia after 48 weeks of ...

Tardive dyskinesia (TD) can make it feel like your body isn't your own. TD causes involuntary movements of your face, arms, legs, and neck that you can't control. TD can make you blink your eyes ...

US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 ...

Tardive dyskinesia, a neurological disorder that causes repetitive involuntary movements. These results presented at the 2024 Psych Congress Include Data From More Than 300 Patients. Ingrezza was ...